128 related articles for article (PubMed ID: 12003186)
1. Phase II trial of amonafide in central nervous system tumors: a Southwest Oncology Group study.
Taylor SA; Rankin C; Townsend JJ; Craig JB; Vance RB; Solank DL; Brown TD; Jaeckle K;
Invest New Drugs; 2002 Feb; 20(1):113-5. PubMed ID: 12003186
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of amonafide for the treatment of advanced, hormonally refractory carcinoma of the prostate. A Southwest Oncology Group study.
Marshall ME; Blumenstein B; Crawford ED; Thompson IM; Craig JB; Eisenberger M; Ahmann F
Am J Clin Oncol; 1994 Dec; 17(6):514-5. PubMed ID: 7977172
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of mitonafide with a 3-day administration schedule: early interruption due to severe central nervous system toxicity.
Díaz-Rubio E; Martín M; López-Vega JM; Casado A; Benavides A
Invest New Drugs; 1994; 12(4):277-81. PubMed ID: 7775127
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of amonafide in advanced and recurrent sarcoma patients.
Perez RP; Nash SL; Ozols RF; Comis RL; O'Dwyer PJ
Invest New Drugs; 1992 Jul; 10(2):99-101. PubMed ID: 1500272
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of gallium nitrate, amonafide and teniposide in metastatic non-small cell lung cancer. An Eastern Cooperative Oncology Group study (E2588).
Chang AY; Tu ZN; Smith JL; Bonomi P; Smith TJ; Wiernik PH; Blum R
Invest New Drugs; 1995; 13(2):137-41. PubMed ID: 8617576
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of amonafide in patients with advanced metastatic or recurrent endometrial adenocarcinoma. A Southwest Oncology Group study.
Malviya VK; Liu PY; O'Toole R; Alberts DS; Surwit E; Rosenoff S; Ward JH; Yu A; O'Sullivan J; Craig JB
Am J Clin Oncol; 1994 Feb; 17(1):37-40. PubMed ID: 8311005
[TBL] [Abstract][Full Text] [Related]
7. A phase II trial of amonafide in patients with endometrial cancer: a Gynecologic Oncology Group Study.
Asbury R; Blessing JA; Reid GC; McGuire WP
Am J Clin Oncol; 1998 Aug; 21(4):406-7. PubMed ID: 9708643
[TBL] [Abstract][Full Text] [Related]
8. Phase II evaluation of amonafide in advanced sarcoma: a Southwest Oncology Group study.
Buys SS; Metch B; Balcerzak SP; Neefe JR; Stuckey WJ
Cancer Invest; 1994; 12(4):399-402. PubMed ID: 8032960
[TBL] [Abstract][Full Text] [Related]
9. An ECOG phase II study of amonafide in unresectable or recurrent carcinoma of the head and neck (PB390). Eastern Cooperative Oncology Group.
Leaf AN; Neuberg D; Schwartz EL; Wadler S; Ritch PS; Dutcher JP; Adams GL
Invest New Drugs; 1997; 15(2):165-72. PubMed ID: 9220297
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of amonafide in advanced colorectal cancer: a SouthWest Oncology Group study.
Brown TD; Goodman PJ; Fleming T; Macdonald JS; Craig JB; Einstein AB
Anticancer Drugs; 1993 Feb; 4(1):49-50. PubMed ID: 8457714
[TBL] [Abstract][Full Text] [Related]
11. A phase II trial of amonafide in patients with mixed mesodermal tumors of the uterus: a Gynecologic Oncology Group study.
Asbury R; Blessing JA; Podczaski E; Ball H
Am J Clin Oncol; 1998 Jun; 21(3):306-7. PubMed ID: 9626805
[TBL] [Abstract][Full Text] [Related]
12. Amonafide in patients with leiomyosarcoma of the uterus: a phase II Gynecologic Oncology Group study.
Asbury R; Blessing JA; Buller R; Malfetano JH; Walker J; Sevin BU
Am J Clin Oncol; 1998 Apr; 21(2):145-6. PubMed ID: 9537200
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of amonafide in refractory and relapsing multiple myeloma: a Southwest Oncology Group study.
Hanson KH; Crowley J; Salmon SE; Keppen M; Braun TJ; Bonnet JD
Anticancer Drugs; 1991 Jun; 2(3):247-50. PubMed ID: 1802018
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of amonafide in advanced pancreas cancer. A Southwest Oncology Group study.
Leichman CG; Tangen C; Macdonald JS; Leimert T; Fleming TR
Invest New Drugs; 1993; 11(2-3):219-21. PubMed ID: 8262735
[TBL] [Abstract][Full Text] [Related]
15. Amonafide: An active agent in the treatment of previously untreated advanced breast cancer--a cancer and leukemia group B study (CALGB 8642).
Costanza ME; Berry D; Henderson IC; Ratain MJ; Wu K; Shapiro C; Duggan D; Kalra J; Berkowitz I; Lyss AP
Clin Cancer Res; 1995 Jul; 1(7):699-704. PubMed ID: 9816035
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of amonafide in gastric adenocarcinoma. An Illinois Cancer Center trial.
Mullane MR; Schilsky RL; Carroll RB; Wade JL; Kilton LJ; Blough RR; Bauman A; French SL; Benson AB
Invest New Drugs; 1994; 12(3):267-70. PubMed ID: 7896548
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of amonafide in disseminated malignant melanoma. A Southwest Oncology Group study.
Slavik M; Kopecky KJ; Sondak V; Craig JB; Samson MK
Invest New Drugs; 1993; 11(2-3):223-6. PubMed ID: 8262736
[TBL] [Abstract][Full Text] [Related]
18. A Gynecologic Oncology Group phase II study of amonafide (NSC 308847) in epithelial ovarian cancer.
Asbury RF; Blessing JA; Look KY; Clarke-Pearson D; Homesley HD
Am J Clin Oncol; 1993 Dec; 16(6):529-31. PubMed ID: 8256772
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of amonafide (nafidamide, NSC 308847) in advanced colorectal cancer.
O'Dwyer PJ; Paul AR; Hudes GR; Walczak J; Ozols RF; Comis RL
Invest New Drugs; 1991 Feb; 9(1):65-7. PubMed ID: 2026485
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of amonafide in previously treated patients with advanced ovarian cancer: a Southwest Oncology Group study.
Gallion HH; Liu PY; Alberts DE; O'Toole RV; O'Sullivan J; Mills G; Smith HO; Hynes HE
Gynecol Oncol; 1992 Aug; 46(2):230-2. PubMed ID: 1500027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
